- Home
- SYBT vs CRVS Comparison
SYBT vs CRVS Comparison
Compare SYBT & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SYBT | CRVS |
|---|---|---|
| Founded | 1904 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | SYBT | CRVS |
|---|---|---|
| Price | $69.73 | $18.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $80.33 | $28.00 |
| AVG Volume (30 Days) | 117.8K | ★ 7.8M |
| Earning Date | 01-27-2026 | 03-24-2026 |
| Dividend Yield | ★ 1.87% | N/A |
| EPS Growth | ★ 22.11 | N/A |
| EPS | ★ 4.75 | N/A |
| Revenue | ★ $390,560,000.00 | N/A |
| Revenue This Year | $16.90 | N/A |
| Revenue Next Year | $7.91 | N/A |
| P/E Ratio | $14.43 | ★ N/A |
| Revenue Growth | ★ 14.02 | N/A |
| 52 Week Low | $60.75 | $2.54 |
| 52 Week High | $83.83 | $26.95 |
Technical Indicators
Market Signals| Indicator | SYBT | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 52.14 | 58.55 |
| Support Level | $66.98 | $18.50 |
| Resistance Level | $71.84 | $19.94 |
| Average True Range (ATR) | 1.90 | 1.48 |
| MACD | -0.05 | -0.63 |
| Stochastic Oscillator | 51.03 | 18.96 |
Price Performance
Historical ComparisonAbout SYBT Stock Yards Bancorp Inc.
Stock Yards Bancorp Inc operates as a bank. The bank has two reportable operating segments namely Commercial Banking and Wealth Management and Trust. Its services include loan and deposit services, cash management services, securities brokerage activities, mortgage origination, and others. It generates the majority of its revenue from the Commercial Banking segment.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).